Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib | Zendy

Caroline Robert | Zendy; Bogusława Karaszewska | Zendy; Jacob Schachter | Zendy; Piotr Rutkowski | Zendy; Andrzej Maćkiewicz | Zendy; D. Stroiakovski | Zendy; M. Lichinitser | Zendy; Reinhard Dummer | Zendy; Florent Grange | Zendy; Laurent Mortier | Zendy; Vanna ChiarionSileni | Zendy; Kamil Drucis | Zendy; Ivana Krajsová | Zendy; Axel Hauschild | Zendy; Paul Lorigan | Zendy; Pascal Wolter | Zendy; Georgina V. Long | Zendy; Keith T. Flaherty | Zendy; Paul Nathan | Zendy; Antoni Ribas | Zendy; Anne-Marie Martin | Zendy; Peng Sun | Zendy; Wendy Crist | Zendy; Jeff Legos | Zendy; Stephen D. Rubin | Zendy; Shonda M Little | Zendy; Dirk Schadendorf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Author(s) -

Caroline Robert,

Bogusława Karaszewska,

Jacob Schachter,

Piotr Rutkowski,

Andrzej Maćkiewicz,

D. Stroiakovski,

M. Lichinitser,

Reinhard Dummer,

Florent Grange,

Laurent Mortier,

Vanna ChiarionSileni,

Kamil Drucis,

Ivana Krajsová,

Axel Hauschild,

Paul Lorigan,

Pascal Wolter,

Georgina V. Long,

Keith T. Flaherty,

Paul Nathan,

Antoni Ribas,

Anne-Marie Martin,

Peng Sun,

Wendy Crist,

Jeff Legos,

Stephen D. Rubin,

Shonda M Little,

Dirk Schadendorf

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1412690

Subject(s) - dabrafenib , vemurafenib , trametinib , medicine , hazard ratio , melanoma , interim analysis , oncology , confidence interval , adverse effect , combination therapy , randomized controlled trial , metastatic melanoma , cancer research , cancer , mapk/erk pathway , kinase , biology , microbiology and biotechnology

The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research